CN103732231B - 炎性病症的预防和治疗 - Google Patents

炎性病症的预防和治疗 Download PDF

Info

Publication number
CN103732231B
CN103732231B CN201280039650.6A CN201280039650A CN103732231B CN 103732231 B CN103732231 B CN 103732231B CN 201280039650 A CN201280039650 A CN 201280039650A CN 103732231 B CN103732231 B CN 103732231B
Authority
CN
China
Prior art keywords
type
cells
nkt
liver
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201280039650.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN103732231A (zh
Inventor
维品·库马尔·查图尔维迪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gerry Bio
Gregory Immunotherapy
Original Assignee
Gerry Bio
Gregory Immunotherapy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gerry Bio, Gregory Immunotherapy filed Critical Gerry Bio
Priority to CN202010113948.3A priority Critical patent/CN111298120A/zh
Publication of CN103732231A publication Critical patent/CN103732231A/zh
Application granted granted Critical
Publication of CN103732231B publication Critical patent/CN103732231B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201280039650.6A 2011-06-24 2012-06-22 炎性病症的预防和治疗 Active CN103732231B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010113948.3A CN111298120A (zh) 2011-06-24 2012-06-22 炎性病症的预防和治疗

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161501139P 2011-06-24 2011-06-24
US61/501,139 2011-06-24
PCT/US2012/043875 WO2012178108A1 (en) 2011-06-24 2012-06-22 Prevention and treatment of inflammatory conditions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202010113948.3A Division CN111298120A (zh) 2011-06-24 2012-06-22 炎性病症的预防和治疗

Publications (2)

Publication Number Publication Date
CN103732231A CN103732231A (zh) 2014-04-16
CN103732231B true CN103732231B (zh) 2020-04-10

Family

ID=47422987

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201280039650.6A Active CN103732231B (zh) 2011-06-24 2012-06-22 炎性病症的预防和治疗
CN202010113948.3A Pending CN111298120A (zh) 2011-06-24 2012-06-22 炎性病症的预防和治疗

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202010113948.3A Pending CN111298120A (zh) 2011-06-24 2012-06-22 炎性病症的预防和治疗

Country Status (13)

Country Link
US (3) US9949996B2 (https=)
EP (2) EP3616701A1 (https=)
JP (2) JP6441073B2 (https=)
KR (2) KR102055395B1 (https=)
CN (2) CN103732231B (https=)
AU (1) AU2012272642B2 (https=)
BR (1) BR112013033309B1 (https=)
CA (1) CA2840272C (https=)
DK (1) DK2723347T3 (https=)
ES (1) ES2759584T3 (https=)
MX (1) MX367850B (https=)
RU (1) RU2678561C9 (https=)
WO (1) WO2012178108A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012272642B2 (en) 2011-06-24 2017-09-07 Gri Bio, Inc. Prevention and treatment of inflammatory conditions
WO2014113695A1 (en) 2013-01-18 2014-07-24 Cornell University Methods of treating diseases associated with high fat diet and vitamin a deficiency using retinoic acid receptor agonists
US11191755B2 (en) 2014-01-17 2021-12-07 Cornell University Compositions and methods for providing cardioprotective effects
CA2937107C (en) * 2014-01-17 2020-12-22 Cornell University Methods of treating metabolic syndrome related conditions using retinoic acid receptor agonists
JP2017507950A (ja) 2014-02-27 2017-03-23 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ レチノイン酸受容体関連オーファン受容体ガンマのアゴニストを使用する養子細胞療法及び関連治療方法
WO2015138354A1 (en) * 2014-03-10 2015-09-17 Cornell University Combination therapy for head and neck cancer
JP6523337B2 (ja) 2014-05-05 2019-05-29 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ ＲＯＲγのアゴニストとしての使用及び疾患治療のためのベンゼンスルホンアミド及び関連化合物
EP3140291A4 (en) 2014-05-05 2018-01-10 Lycera Corporation Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
ES2860823T3 (es) 2014-12-09 2021-10-05 Gri Bio Inc Prevención y tratamiento de afecciones inflamatorias
US10421751B2 (en) 2015-05-05 2019-09-24 Lycera Corporation Dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
AU2016276947A1 (en) 2015-06-11 2017-12-14 Lycera Corporation Aryl dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease
EP3650045B1 (en) 2017-07-04 2024-11-13 Daiichi Sankyo Company, Limited Drug for retinal degenerative disease associated with photoreceptor degeneration
EP3806839B1 (en) * 2018-06-14 2024-08-07 Cornell University Cornell Center For Technology, Enterprise & Commercialization ("CCTEC") Retinoic acid receptor-beta2 agonist with cardioprotective effects
US12115140B2 (en) 2020-07-31 2024-10-15 The Trustees Of Columbia University In The City Of New York Method of treating adenoid cystic carcinoma
CN113207799B (zh) * 2021-03-19 2022-03-15 中山大学 一种二型糖尿病小鼠快速心衰模型的构建方法
EP4401829A4 (en) * 2021-09-15 2025-07-16 Univ Cornell COMPOSITIONS AND METHODS FOR ALLEVIATING ALCOHOLIC LIVER DISEASE

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1203528A (zh) * 1995-10-09 1998-12-30 盖尔德马皮肤病学国际研究中心 RAR－γ特异性激动剂配体用于提高细胞程序死亡率

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE59777B1 (en) 1985-12-04 1994-04-06 Max Planck Gesellschaft Medicaments
JP3879938B2 (ja) * 1994-03-31 2007-02-14 日本ケミカルリサーチ株式会社 抗炎症剤
JPH08109134A (ja) * 1994-10-11 1996-04-30 Sanwa Kagaku Kenkyusho Co Ltd 細胞変成抑制並びに臓器毒性軽減剤
US6025388A (en) 1995-04-26 2000-02-15 Allergan Sales, Inc. Method for inhibiting gene expression promoted by AP1 protein with RARβ selective retinoids and method for treatment of diseases and conditions with such retinoids
US5624957A (en) * 1995-06-06 1997-04-29 Bristol-Myers Squibb Company Rary-specific retinobenzoic acid derivatives
US5965606A (en) 1995-12-29 1999-10-12 Allergan Sales, Inc. Methods of treatment with compounds having RAR.sub.α receptor specific or selective activity
CA2263817A1 (en) * 1996-08-28 1998-03-05 Centre National De La Recherche Scientifique Therapeutic combinations of rar antagonists and rxr agonists and use thereof
DK1051159T3 (da) 1998-01-22 2002-08-05 Zentaris Ag Faste farmaceutiske præparater indeholdende miltefosin til oral administration ved behandling af leishmaniasis
JO2178B1 (en) 1999-10-19 2003-04-23 اف . هوفمان لاروش ايه جي Treatment of emphysema using rar selective retinoid antagonists
US7390795B2 (en) 2000-12-18 2008-06-24 Pentraxin Therapeutics Limited Treatment and prevention of tissue damage
EP1372668B1 (en) * 2001-03-26 2011-12-07 Dana-Farber Cancer Institute, Inc. Method of attenuating reactions to skin irritants
CA2509955A1 (en) * 2002-11-29 2004-06-17 Gpc Biotech Ag Formulations useful against hepatitis c virus infections
US20050026950A1 (en) * 2003-07-30 2005-02-03 Allergan, Inc. Methods of therapeutic treatment using retinoids to achieve consistent bioavailability
CN1210041C (zh) 2003-09-29 2005-07-13 中国医学科学院皮肤病研究所 治疗痤疮的复方外用药物
WO2005120479A1 (en) * 2004-06-09 2005-12-22 Gpc Biotech Ag Use of selenium or a selenium salt and a retinoid acid or a retinoid in the treatment of viral hepatitis c
US20110118197A1 (en) * 2005-09-29 2011-05-19 Vipin Kumar Chaturvedi Prevention of hepatic ischemic reperfusion injury by administration of sulfatides
DE602006019759D1 (de) * 2005-09-29 2011-03-03 Torrey Pines Inst Sulfatide zur behandlung von autoimmunkrankheiten
JP2009520730A (ja) 2005-12-23 2009-05-28 ヤド・テヒノロギース・ゲーエムベーハー アレルギー性疾患を治療および予防するための手段および方法
DE102006019906A1 (de) 2006-04-28 2007-10-31 Müller-Enoch, Dieter, Prof. Dr. Verwendung von Verbindungen der Formel A-R-X oder deren pharmazeutisch akzeptable Salze zur Herstellung einer pharmazeutischen Zubereitung
EP2097075A1 (fr) * 2006-11-20 2009-09-09 Galderma Research & Development, S.N.C. Utilisation d'adapalène pour moduler l'expression de cd1d ou il-10.
CN102595892B (zh) * 2009-07-16 2014-09-10 施泰福实验室股份有限公司 他扎罗汀衍生物
IT1403356B1 (it) 2010-12-27 2013-10-17 Sit La Precisa Spa Con Socio Unico Dispositivo per il controllo dell'erogazione di un gas combustibile verso un bruciatore, particolarmente per apparecchi riscaldatori di acqua
WO2012160186A1 (en) 2011-05-26 2012-11-29 Jado Technologies Gmbh Oxygenated amino- or ammonium-containing sulfonic acid, phosphonic acid and carboxylic acid derivatives and their medical use
AU2012272642B2 (en) 2011-06-24 2017-09-07 Gri Bio, Inc. Prevention and treatment of inflammatory conditions
US9005490B2 (en) 2012-12-14 2015-04-14 Delphi Technologies, Inc. Material for solid state sintered material
WO2014166941A1 (en) 2013-04-08 2014-10-16 Academisch Medisch Centrum Miltefosin or perifosin for use in the treatment of ibd
ES2860823T3 (es) 2014-12-09 2021-10-05 Gri Bio Inc Prevención y tratamiento de afecciones inflamatorias

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1203528A (zh) * 1995-10-09 1998-12-30 盖尔德马皮肤病学国际研究中心 RAR－γ特异性激动剂配体用于提高细胞程序死亡率

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Liver natural killer and natural killer T cells: immunobiology and emerging roles in liver diseases;Bin Gao, et al.;《Journal of Leukocyte Biology》;20090930;第86卷;513-528 *
Tazarotene 0.1% gel is associated with alterations in markers of epidermal differentiation and inflammation in psoriatic plaques;C HAGER, et al.;《THE JOURNAL OF INVESTIGATIVE DERMATOLOGY》;19970427;第108卷(第4期);656 *

Also Published As

Publication number Publication date
KR102055395B1 (ko) 2019-12-12
DK2723347T3 (da) 2019-11-18
EP3616701A1 (en) 2020-03-04
RU2678561C9 (ru) 2019-03-05
RU2014100056A (ru) 2015-07-27
JP2017206523A (ja) 2017-11-24
JP2014517077A (ja) 2014-07-17
CA2840272A1 (en) 2012-12-27
KR102164567B1 (ko) 2020-10-12
CN103732231A (zh) 2014-04-16
CA2840272C (en) 2020-09-15
BR112013033309B1 (pt) 2022-07-05
KR20140048939A (ko) 2014-04-24
US10925886B2 (en) 2021-02-23
BR112013033309A2 (pt) 2017-03-07
EP2723347A4 (en) 2015-02-25
KR20190140087A (ko) 2019-12-18
RU2678561C2 (ru) 2019-01-30
US20180193368A1 (en) 2018-07-12
ES2759584T3 (es) 2020-05-11
US11660309B2 (en) 2023-05-30
MX2013015441A (es) 2014-09-22
US9949996B2 (en) 2018-04-24
EP2723347A1 (en) 2014-04-30
AU2012272642A1 (en) 2014-01-30
US20140187504A1 (en) 2014-07-03
CN111298120A (zh) 2020-06-19
AU2012272642A2 (en) 2014-02-13
EP2723347B1 (en) 2019-09-04
WO2012178108A1 (en) 2012-12-27
AU2012272642B2 (en) 2017-09-07
MX367850B (es) 2019-09-09
JP6441073B2 (ja) 2018-12-19
BR112013033309A8 (pt) 2018-03-06
US20210169909A1 (en) 2021-06-10

Similar Documents

Publication Publication Date Title
CN103732231B (zh) 炎性病症的预防和治疗
JP2014517077A5 (https=)
JP7573056B2 (ja) 炎症性病態の予防および治療
RU2789326C1 (ru) Предупреждение и лечение воспалительных состояний
HK40076925A (en) Prevention and treatment of inflammatory conditions
RU2843587C1 (ru) Предотвращение и лечение воспалительных состояний
HK1192159A (en) Prevention and treatment of inflammatory conditions
HK1192159B (en) Prevention and treatment of inflammatory conditions
HK1243961B (en) Prevention and treatment of inflammatory conditions

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: American California

Applicant after: Gerry Bio

Address before: American California

Applicant before: GLYCOREGIMMUNE INC.

GR01 Patent grant
GR01 Patent grant